secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirum Pharmaceuticals, Inc. (MIRM)
CIK:        0001759425
Form:       8-K
Filed at:   2021-08-20T23:59:59+00:00
Accession:  0001193125-21-251740
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirum appoints William Fairey to board, replacing Tiba Aynechi
--------------------------------------------------------------

- Tiba Aynechi resigned from the board effective August 19, 2021; no dispute or disagreement cited.
- William Fairey appointed to board effective August 19, 2021; will serve as Class I director through 2023 annual meeting.
- Fairey granted stock option for 34,000 shares vesting over 3 years; annual cash retainer of $40K plus $10K for Audit Committee.
- Fairey brings ~30 years biotech commercial experience; previously at MyoKardia, ChemoCentryx, and Actelion.
- Company preparing for first U.S. product launch; board also appointed Carol Brosgart and Patrick Heron to committees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759425/000119312521251740/0001193125-21-251740-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759425/000119312521251740/d216866d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-251740

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer